BioSpace News Archive

Altavant Sciences announced today that the company will make an oral presentation on preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans.

The American Diabetes Association® is pleased to announce the opening of a new nomination window for the Pathway to Stop Diabetes® research grants in 2022.

TeDan Surgical Innovations, leader in the development and commercialization of surgical access systems continues to address evolving surgical access techniques to the spine through the market release of the Phantom UL™ Anterior to the Psoas Surgical Access System.

Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter 2022 earnings results after market close on Monday, May 9, 2022.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company announced that Xenon’s management team will participate in the following investor conferences.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present.

BELLUS Health Inc. announced that the Company’s management team will participate in multiple upcoming investor conferences.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2022 after the market closes on Tuesday, May 3, 2022.

DBV Technologies announced that the Company will host a conference call and live audio webcast on Thursday, May 2, 2022, at 5:00 p.m. ET to report first quarter 2022 financial results and provide a corporate update.

Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF (Pulsed Electro-Magnetic Field) product SofPulse®.